aTyr Pharma, Inc. (ATYR) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 2 Buy, 7 Hold.
The consensus price target is $5.13 (low: $1.00, high: $17.00), representing an upside of 510.1% from the current price $0.84.
Analysts estimate Earnings Per Share (EPS) of $-0.91 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.86 vs est $-0.91 (beat +5.6%). 2025: actual $-0.80 vs est $-0.83 (beat +3.9%). Analyst accuracy: 95%.
ATYR Stock — 12-Month Price Forecast
$5.13
▲ +510.06% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for aTyr Pharma, Inc., the average price target is $5.13, with a high forecast of $17.00, and a low forecast of $1.00.
The average price target represents a +510.06% change from the last price of $0.84.
Highest Price Target
$17.00
Average Price Target
$5.13
Lowest Price Target
$1.00
ATYR Analyst Ratings
Hold
Based on 9 analysts giving stock ratings to aTyr Pharma, Inc. in the past 3 months
EPS Estimates — ATYR
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.86
vs Est –$0.91
▲ 5.9% off
2025
Actual –$0.80
vs Est –$0.83
▲ 4.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ATYR
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 10.1% off
2025
Actual $0.000B
vs Est $0.000B
▲ 23.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
